Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy

Curr Diab Rep. 2016 Dec;16(12):122. doi: 10.1007/s11892-016-0825-4.


The prevalence of diabetes is growing at epidemic rates in the USA. Diabetic retinopathy develops in a large proportion of patients and is a leading cause of blindness worldwide. Systemic management of diabetic retinopathy has included glycemic, hypertension, and lipid control. Local ophthalmic treatment in the form of focal/grid or panretinal laser photocoagulation has been shown to prevent vision loss in diabetic edema and proliferative diabetic retinopathy, respectively. The introduction of anti-vascular endothelial growth factor for diabetic macular edema and retinopathy has provided clinicians with improved clinical outcomes with potentially less damaging effects than laser.

Keywords: Aflibercept; Bevacizumab; DME; Diabetes; Diabetic macular edema; Diabetic retinopathy; Ranibizumab.

Publication types

  • Review

MeSH terms

  • Diabetic Retinopathy / drug therapy*
  • Humans
  • Laser Coagulation
  • Macular Edema / drug therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*


  • Vascular Endothelial Growth Factor A